Gillian is the Chief Scientific Officer at Juvenescence UK LTD since October 2023 and has 30+ years of experience in research, development, approval, and commercialization of new medicines in both “Big Pharma” and as an entrepreneur in the biotech environment. She holds a Master of Science in Toxicology from the University of Surrey and a Bachelor of Science from University of Leeds in Biochemistry and Genetics. Before her current role in Juvenescence, she was Senior Vice President and Head of Research and Early Development at Jazz Pharmaceuticals, SVP R&D Operations at GW Pharmaceuticals and also VP Head of New Medicines Strategic Planning at UCB. One of her key roles in 2008 was Company Director and Chief Development Officer at RespiVert, a UK based biotech that delivered clinical phase assets from start-up to acquisition by global pharma player in only 18 months, within £20M budget. Her previous experience covers various leadership roles at GlaxoSmithKline. In her career she led 20+ novel medicines and devices through successful IND and clinical submissions in areas of respiratory, immunology, rare disease, anti-infective and neurology therapy areas. Gillian is member of the BD committee. She is English